Skip to main content
RFL
NYSE Life Sciences

Rafael Proxy Seeks 2.42M More Plan Shares to Enable 1.93M Options Tied to FDA Approval

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Real Estate Services Stocks · Real Estate
Sentiment info
Neutral
Importance info
7
Price
$1.08
Mkt Cap
$55.85M
52W Low
$0.99
52W High
$3.96
52W Position info
9.1% above low
Off High info
73% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

RFL is trading near its 52-week low of $0.99 (9.1% above the low) on light trading volume (0.2× avg).

Summary

Rafael's definitive proxy asks shareholders to add 2,422,483 shares to the 2021 Equity Incentive Plan — the condition for 1,925,670 options granted in August 2026 to remain exercisable — alongside routine director elections, auditor ratification and say-on-pay at the January 7, 2027 meeting.


Key Events · Corporate Governance and Compliance · RFL

  • Proxy Sets January 7 Meeting

    Shareholders of record on November 10, 2026 will vote on six director nominees, ratification of CohnReznick for fiscal 2027, the 2021 Plan amendment and an advisory say-on-pay vote.

  • Plan Expansion Enables 1.93M Options

    Proposal 3 raises the 2021 Plan pool by 2,422,483 shares, from 4,365,795 to 6,788,278, which is required for the 1,925,670 options granted August 18, 2026 at $1.87 to be exercisable.

  • Vesting Hinges on FDA Approval

    Half the options vest only on FDA approval of Trappsol Cyclo plus issuance of a priority review voucher, 25% on the 12-month and 25% on the 24-month anniversary; all are forfeited if approval is not obtained by August 12, 2027.

  • Insider Grants Concentrated

    Of the August 2026 grants, Howard Jonas received 728,170 options, Joshua Fine 390,000 and David Polinsky 165,000, with 642,500 going to other employees and consultants.


Analysis · RFL · Life Sciences

The annual meeting itself is routine, but Proposal 3 is not: the August 18, 2026 option grants to management and consultants — 1,925,670 shares at $1.87 — are void unless shareholders expand the 2021 Plan by 2,422,483 shares. Those options only pay off if the FDA approves Trappsol Cyclo and issues a priority review voucher by August 12, 2027, so the vote is effectively a referendum on the NDA filed in October. Against a going-concern warning and $22.1 million of cash, the plan expansion also adds a fresh equity overhang on top of the existing 52.2 million shares outstanding.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RFL was trading at $1.08 on NYSE in the Life Sciences sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $0.99 to $3.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RFL - Latest Insights

RFL
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.08 info
Change: -$0.115 (-10%) info
Market Cap: $55.85M info
RFL
Oct 29, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $1.08 info
Change: -$0.060 (-5%) info
Market Cap: $55.85M info
RFL
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $1.08 info
Change: -$0.060 (-5%) info
Market Cap: $55.85M info
RFL
Sep 30, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.08 info
Change: -$0.240 (-18%) info
Market Cap: $55.85M info
RFL
Sep 30, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $1.08 info
Change: -$0.160 (-13%) info
Market Cap: $55.85M info